Clostridium difficile is the most common cause of nosocomial diarrhea in the United States and Europe, and is a cause of significant morbidity and mortality among hospitalized patients. A newly identified epidemic strain has been associated with many hospital outbreaks of C. difficile-associated disease (CDAD), raising the concern of an escalating burden of CDAD among at-risk patients. Hematopoietic SCT (HSCT) recipients are known to be at increased risk for a wide variety of infectious complications, including CDAD as a result of prolonged hospitalizations, exposure to broad-spectrum antibiotics, altered integrity of the intestinal mucosa and GVHD. The incidence of CDAD in the HSCT population has been reported as high as 20% in some large series. The frequency and seriousness of CDAD in this defined group as compared with the general hospital population, however, are not clearly delineated. We discuss the epidemiology and diagnosis of CDAD and review recent studies examining the risk factors and characteristics of CDAD in HSCT recipients. Finally, we provide a management algorithm for the diagnosis and treatment of CDAD at our institution.
Introduction
Clostridium difficile has long been recognized as the most common and most serious cause of nosocomial diarrhea in the United States. Over the past several years, the incidence and severity of C. difficile-associated disease (CDAD) have risen significantly in North America as well as in Europe. [1] [2] [3] [4] [5] The re-emergence of CDAD has been associated, in part, with the detection of a new hypervirulent strain of C. difficile known as the North American pulsed-field gel electrophoresis type 1 (NAP-1) strain. [6] [7] [8] [9] [10] [11] In addition, there is growing concern regarding the selection of the optimal therapy for severe CDAD as well as the significant rate of recurrent disease after initially successful treatment regimens. [1] [2] [3] [4] [5] Hematologic stem cell transplant (HSCT) recipients have a large number of well-recognized risk factors for the development of CDAD. However, despite the newfound appreciation of CDAD as a cause of nosocomial diarrhea and colitis, the role of C. difficile-mediated gastrointestinal morbidity and mortality among HSCT recipients remains incompletely understood. In this review, we examine the literature related to CDAD in HSCT recipients, outline the current state of the art regarding treatment for this condition and highlight newer and investigational forms of therapy.
Pathophysiology and epidemiology of CDAD
CDAD develops when a patient ingests the spores of a toxigenic strain of C. difficile in the setting of an abnormal or disrupted colonic mucosa. [1] [2] [3] [4] [5] In this instance, toxigenic strains are induced to produce two large clostridial exotoxins, C. difficile toxin A (TcdA) and toxin B (TcdB). [12] [13] [14] These toxins are directly responsible for the colonic inflammation and necrosis that are typical of CDAD. A variety of insults are known to disrupt the integrity of the colonic epithelium, but exposure to antibiotics, cytotoxic chemotherapy and gastrointestinal surgery are the commonest predisposing factors. [1] [2] [3] [4] [5] In addition to these primary factors, a number of additional co-factors are known to increase the risk of CDAD in an individual patient and include advanced age, medical comorbidities, long hospital stays, suppression of gastric acid production by H2 blockers and proton pump inhibitors, enteral intubation or feeding, and the number, type and duration of antibiotic exposure. [1] [2] [3] [4] [5] [8] [9] [10] [11] Specific antibiotic exposure risk varies somewhat between studies, but the antibiotics most commonly showing an increased risk for CDAD include clindamycin, extended spectrum cephalosporins and quinolones. [1] [2] [3] [4] [5] [8] [9] [10] [11] Antibiotics believed to have a decreased risk of CDAD include vancomycin, tetracyclines, macrolides and aminoglycosides. HSCT recipients in particular are known to be subjected to a variety of risk factors for CDAD, such as prolonged hospital stays, longterm and broad-spectrum antibiotic use, altered integrity of the intestinal mucosa from chemoradiation therapy and GVHD.
Over the past several years, the incidence and severity of CDAD have increased notably in many areas of North America, the United Kingdom and Europe. [1] [2] [3] [4] [5] [8] [9] [10] [11] In addition to the classical strain of C. difficile, a newly identified epidemic strain has been found responsible for the increased burden of CDAD in many of these areas (Table 1) .
6-11 C. difficile strains are typed by the use of restriction enzyme analysis, pulsed-field gel electrophoresis and toxinotyping (through restriction fragment length polymorphisms of the pathogenicity locus). The so-called epidemic strain, for example, is also described as ribotype 27, NAP-1 and toxinotype III. [6] [7] [8] [9] [10] [11] The NAP-1 and related strains differ notably from the classical strains of C. difficile in that they contain an abnormal version of the toxin repressor gene tcdC. As a result, these variant strains can produce extremely high concentrations of the C. difficile toxins. [6] [7] [8] [9] [10] [11] In addition, these epidemic strains also contain a gene (cdtB) encoding a distinctive form of exotoxin known as binary toxin. Production of the binary toxin, which is homologous to Clostridium perfringens iota toxin, appears to be associated with more severe forms of CDAD. [6] [7] [8] [9] [10] [11] Smaller outbreaks of nosocomial disease have also been reported for other NAP-1-like strains of C. difficile (Table 1) .
Acquisition of a toxigenic strain of C. difficile alone is not sufficient to cause CDAD. It is estimated that 1-5% of the general population is colonized with toxigenic C. difficile, although up to 20% of hospitalized patients may become colonized during their stay. [1] [2] [3] [4] [5] [8] [9] [10] [11] Clinical disease caused by C. difficile includes asymptomatic colonization, mild diarrhea, pseudomembranous colitis, toxic megacolon and even death. As noted above, the pathophysiology of CDAD depends on the secretion and cellular action of two specific toxins, TcdA and TcdB. [12] [13] [14] These clostridial exotoxins exert their cellular effects through their glucosyltranserase activity by targeting and disrupting the intracellular signaling pathways regulated by the Rho family of small GTPases. [12] [13] [14] [15] [16] Altered cellular function caused by TcdA and TcdB disrupts colonic mucosal integrity, activates colonic epithelial cell apoptosis and induces the secretion of a variety of pro-inflammatory cytokines. [12] [13] [14] Many of these effects direct the recruitment of neutrophils (PMN) to the site of toxin action. PMN infiltration is the hallmark of a severe form of CDAD known as pseudomembranous colitis.
In view of this picture of the pathophysiology of CDAD, neutropenia, which occurs at some point for most HSCT recipients, would be predicted to have a profound effect on the pathophysiology of CDAD. However, little is known about how quantitative or functional neutropenia modulates the clinical picture and severity of CDAD in the HSCT population. Decreased recruitment and activation of granulocytes theoretically should limit some damage to the colonic epithelium in CDAD. Even so, this potential benefit might be overcome by the direct cytotoxic effect of the toxins on the colonic mucosa and the deleterious effects of secondary bacterial colitis that can occur as a result of CDAD. In addition, most neutropenic patients receive granulocyte-stimulating growth factors. Many of these agents are known to inhibit apoptosis and preserve the function of neutrophils and progenitors, effects that could indirectly enhance the action of the C. difficile toxins.
Diagnosis of CDAD
CDAD typically presents with a syndrome of fever, abdominal cramping, copious diarrhea and leukocytosis. [1] [2] [3] [4] [5] HSCT recipients, although, frequently have fever and may have underlying neutropenia, limiting the value of these diagnostic signs for CDAD. In particular, diarrhea is a common complaint at many points during the course of the typical HSCT period, and differentiating infections from other causes of diarrhea is challenging even for the most astute transplant physician (Table 2 ). Helpful diagnostic tools include toxin assays, imaging and endoscopy. Of these techniques, enzyme immunoassay (EIA) for the presence of toxin in stools and computed tomography imaging (showing colonic thickening) are the most helpful techniques, and results can be achieved fairly rapidly.
C. difficile toxin-specific EIA is a rapid, specific and commonly available test for CDAD. [1] [2] [3] [4] [5] [8] [9] [10] [11] Earlier, the standard EIA available in most hospitals tested for the presence of only TcdA. Most currently available assays can 
Abbreviations: NAP1 ¼ North American pulsed-field gel electrophoresis type 1; PFGE ¼ pulsed-field gel electrophoresis; þ ¼ yes; À ¼ No. CDAD in HSCT recipients D Bobak et al now detect both TcdA and TcdB. It is commonly reported that the false-positive rate for EIA in CDAD can be up to 10% and as many as three replicate assays may be needed to accurately diagnose CDAD. In the last few years, however, reports indicate that only one or two EIA should be sufficient. [1] [2] [3] [4] [5] [8] [9] [10] [11] However, these data are not based on the study of neutropenic or HSCT patients, and the exact specificity and sensitivity of C. difficile toxin EIA in these populations are incompletely understood.
In special cases, a tissue culture-based cytotoxicity assay can also be performed and is considered to be the so-called 'gold standard' for the detection of C. difficile toxin. [1] [2] [3] [4] [5] In vitro, the cytotoxic effect of TcdB is nearly 1000 times greater than that of TcdA, thus a positive cyto-toxicity assay generally indicates the presence of TcdB. [1] [2] [3] [4] [5] [12] [13] [14] This test is not generally commercially available and is typically performed only at reference laboratories. Investigational assays designed to measure the presence of Tcd by antigen or PCR currently are in development and may become available for more general use in the next few years.
CDAD in HSCT recipients
C. difficile has long been identified as a cause of diarrhea in patients undergoing HSCT, although in earlier studies, the role of this pathogen in causing infectious complications often was not characterized in detail. 17 In Table 3 , we identify several of the more recent studies directly or indirectly examining the characteristics of CDAD in HSCT recipients.
Cox et al. 18 examined the etiology of diarrhea in 296 patients undergoing allo-or auto-HSCT for a variety of indications. Of 150 episodes of diarrhea in 126 patients occurring days 20-100 after transplant, the attributions were GVHD (49%), unknown etiology (39%) and infectious causes (13%). Six of 20 patients with infectious diarrhea had CDAD. All six patients had complete marrow reconstitution, were outpatients at diarrhea onset and only two had gut GVHD concurrently with CDAD. Allogeneic transplantation was the only risk factor associated with diarrhea.
Mossad et al. 19 reported early infectious problems in 76 (34.7%) of 219 patients. Only one episode was attributed to CDAD. The authors concluded that the use of hematopoietic growth factors and transplantation with peripheral blood progenitors were associated with fewer infections owing to a shorter neutropenic period. Yuen et al. 20 evaluated 120 hematologic malignancy and severe aplastic anemia patients who underwent HSCT for 'symptoms referable to the alimentary tract' for 1 year after therapy. Of 141 separate episodes of diarrhea, 20 stool cultures were positive for C. difficile organisms and 16 also were positive for C. difficile toxin by assay. Of the 16 patients, 15 (94%) with toxin-positive C. difficile had diarrhea. The authors speculated that the use of ciprofloxacin prophylaxis while preventing infection from common Gram-negative bacteria, allowed the emergence of C. difficile, an organism often resistant to fluoroquinolones.
Bilgrami et al. 21 retrospectively analyzed the incidence, clinical profiles, treatment response and outcome of CDAD in 200 patients receiving auto-HSCT. Fifteen episodes of CDAD occurred within 89 days at a median onset of 33 days. Diarrhea (median duration of 5 days), fever and abdominal cramps were the presenting prodrome symptoms prior to the diagnosis of CDAD. Fourteen patients responded to metronidazole, vancomycin or a combination without complications and only one patient relapsed, but was successfully treated with a repeat course of metronidazole.
Avery et al. 22 randomly assigned 80 auto-HSCT recipients to one of two antibiotic regimens (cephalosporin vs fluoroquinolone based) and determined the incidence of diarrhea and the frequency of CDAD. In the 61 patients (76.3%) who developed diarrhea only 3 (4.9%) had CDAD; in this small series, the authors could not comment on the two different antibiotic regimens in relation to the development of CDAD. Chakrabarti and colleagues 23 retrospectively reviewed 75 HSCT transplant recipients for the incidence, risk factors and outcome of CDAD (World Health Organization toxicity criteria). Of these, 49 (65%) patients developed greater than grade 2 diarrhea, but only 10 patients (13%) developed CDAD from 6 days prior to 72 days after transplantation. Fifty percent developed recurrent disease and there were no fatalities attributed to CDAD. Five of the 10 patients with CDAD also had severe GVHD, whereas only 6 of the 65 patients without CDAD were afflicted (P ¼ 0.004, odds ratio (OR): 9.8). Seventy percent of patients with CDAD also had herpes virus or adenovirus, whereas only 23% of patients without diarrhea had evidence of non-CMV viral infections (P ¼ 0.005, OR: 7.7). Both overall and non-relapse mortality were higher in patients with CDAD than those not affected (P ¼ 0.03, OR: 5.6 and P ¼ 0.02, OR: 5.26, respectively), for example, median survival was 100 days in those with CDAD compared with 41 months in the others. Although there were no deaths directly attributable to CDAD, the authors suggest that CDAD may have aggravated GVHD leading to death.
van Kraaij and colleagues 24 prospectively studied 60 patients receiving auto-or allo-HSCT to determine the incidence and cause of acute diarrhea in the post transplant period. Diarrhea was defined as increased stool liquidity and more than three bowel movements per day. Forty-eight diarrheal episodes occurred affecting 79% of allogeneic recipients and 47% of autologous recipients. Only two episodes were attributable to C. difficile toxin-producing strains, both in autologous transplant recipients. The authors collected surveillance stool cultures from all patients regardless of the presence of diarrhea, and two additional C. difficile toxin-positive stool samples were documented. In addition, seven patients had stool cultures positive for C. difficile without the presence of toxin, three with and four without diarrhea.
Barton and colleagues 25 reported the onset and etiology of infections occurring up to 1 year after auto-HSCT performed for breast cancer. The mean length of hospitalization was 25 days (range of 17-56) and 13 of 127 (11%) of patients developed CDAD. The authors found that CDAD was the second most common infectious complication occurring in this cohort. Gorschlu¨ter et al. 26 analyzed their data on 875 courses of myelosuppressive therapy in 371 patients with hematologic malignancies and reported a 7% incidence of CDAD (61 episodes in 53 patients). Diarrhea was defined as at least two loose stools per day. Patients with and without CDAD did not differ regarding age, gender or malignancy type. The majority of patients were treated with oral metronidazole; and all patients treated with oral vancomycin made a complete recovery. Of the patients with CDAD, 13 (21%) died (all-cause mortality) within 30 days after the diagnosis of CDAD. Five patients with CDAD developed severe enterocolitis and also were deemed treatment failures. Both patients with recurrent CDAD were successfully re-treated with metronidazole. The authors recommended that all HSCT patients with diarrhea have their stool examined for the presence of C. difficile toxin and that oral metronidazole was reasonable first-line therapy if tolerated.
Tomblyn et al. 27 retrospectively analyzed 119 allo-or auto-HSCT recipients treated for a variety of malignancies. Diarrhea was defined as more than three loose stools in 24 h over 2 consecutive days. Of 109 patients (91%) who developed diarrhea, 7 patients (6%) had C. difficile toxin in their stool at the onset of diarrhea. Interestingly, all seven patients affected by CDAD were those who received auto-HSCT and received a chemotherapy-only conditioning.
Jillella and colleagues 28 evaluated 54 patients for evidence of infections during the mobilization period for auto-HSCT. These investigators noted only one case of CDAD among 15 instances of infectious complications in the study population. Outcomes were not reported specifically, although the authors commented that all patients improved and none required management in an intensive care unit setting.
In a retrospective review, Arango et al. 29 observed that 157 (64.8%) of 242 auto-HSCT recipients developed diarrhea, which they defined as semisolid or liquid stool twice or more in 24 h. Of 135 patients who were specifically tested, 15.5% were positive for CDAD. Risk factors associated with the development of CDAD included the use of cephalosporins and i.v. vancomycin, whereas a mobilization regimen with paclitaxel appeared protective against CDAD. The reason for these associations was not clear, although the authors speculated that the use of i.v. vancomycin might have been a marker for patients who were more seriously ill. Nearly all of the patients with CDAD improved with oral metronidazole (20/21). One patient was successfully switched to oral vancomycin because of intolerance to metronidazole. The authors conclude that the two-to three-fold increase in the incidence of CDAD in their study population compared with previously published data was related to the older age of their study population and the testing policy in their institution.
Although as a group these articles present a valuable overview of the general picture of the spectrum of CDAD in HSCT recipients, the variability in study design does not allow for definitive conclusions regarding the details of the epidemiology and management of CDAD in this population. In general, it appears that the risk of acquiring CDAD for HSCT recipients is approximately the same as for other high-risk hospital patients, especially when taking into account the length of stay, intensity of antibiotic exposure and seriousness of other medical co-morbidities. Furthermore, the efficacy of treatment for CDAD in HSCT recipients appears to be roughly equivalent to that observed for other groups of hospitalized patients as well. Additional prospective studies are still needed, particularly those focusing on details of the epidemiology and special factors particular to HSCT recipient. Studies examining the effects of environmental and specific infection control measures likely will prove to be extremely useful in designing regimens to prevent or contain CDAD outbreaks for this high-risk patient population.
Management of CDAD
General management principles for any patient with CDAD include discontinuation or narrowing of implicated antibiotics, adequate fluid and electrolyte resuscitation, avoidance of antiperistaltic agents, institution of appropriate infection control measures and specific anti-C. difficile treatment if indicated (references 1-5,9,30 , Table 4 ). All symptomatic patients should be treated with an agent with activity against CDAD. In patients without ileus, standard regimens of oral metronidazole or vancomycin are recommended for 10-14 days. Interestingly, oral vancomycin remains the only Food and Drug Administrationapproved agent for the treatment of CDAD in the United States. In general, regimens utilizing metronidazole or vancomycin appear to be equally efficacious. [1] [2] [3] [4] [5] 9, 30 Some preliminary data and much theoretical speculation, however, have led to assertions that oral vancomycin may provide a small advantage in patients with more severe diseases and may be better at decreasing the rate of relapse. [30] [31] [32] [33] [34] One recent report suggests that treatment 'failure' with metronidazole may reflect a slower and more variable activity of metronidazole as compared with vancomycin. 33 Although the preferred use of these agents is currently debated, it is clear that metronidazole has more side effects than vancomycin, a drug that also has the advantage of being poorly absorbed and exhibiting near ideal pharmacologic characteristics for treating CDAD. 34 There are few, if any, studies to support combination therapy for CDAD, although it is generally recommended that the seriously ill CDAD patient be treated with a combination of oral vancomycin and i.v. metronidazole. [1] [2] [3] [4] [5] 30 In addition, most experts also recommend consideration of vancomycin-containing enemas in patients with ileus or severely decreased intestinal motility. Again, these recommendations are based on the known pharmacology of the agents rather than published clinical evidence.
Other agents that possess in vitro and limited clinical efficacy data for use in CDAD include nitazoxanide and rifaximin. 4, [35] [36] [37] [38] [39] [40] Each of these drugs is approved in the United States for other types of gastrointestinal infections, and some clinicians have used either alone or in combination with metronidazole or vancomycin in patients with severe or recalcitrant CDAD. There are several small case reports addressing the potential efficacy of using adjuvant agents such as i.v. Ig infusion, probiotics or toxin-binding resins, but there is no consensus on the true value of these agents [1] [2] [3] [4] [5] 8, 30 (Table 4) . As with combination therapy above, patients with severe life-threatening CDAD commonly receive a number of offlabel agents in an attempt to prevent colectomy and reduce morbidity and mortality (Table 4) . Patients with serious CDAD should have a general surgical consultation as partial or total colectomy may be necessary for the most seriously ill patients. [1] [2] [3] [4] [5] Except for the data provided in the studies cited in the preceding section, there are few guidelines for the management of CDAD specifically in HSCT recipients. We organized our current opinion for the approach to the management of CDAD in HSCT recipients in an algorithm presented in Figure 1 . It can be noted that there are no studies to support the use of either rifaximin or nitazoxanide alone or in combination with standard therapy for the treatment of severe CDAD. Based on the theoretical likelihood of benefit, however, we often use one or the other of these agents in combination with vancomycin and metronidazole. On account of the lack of microbial and clinical resistance studies for these newer agents, although, we would not routinely recommend the use of either rifaximin or nitazoxanide alone for the treatment of severe CDAD.
In addition to the use of combination or adjuvant therapies for CDAD, another area of interest and controversy is the treatment of recurrent CDAD. 40 Furthermore, there is a paucity of published data to suggest the optimal approach to the patient with multiple recurrences. Most experts recommend that the first or second recurrence of CDAD be treated with a repeat course of the original agent used. Newer approaches include long, tapered or pulsed courses of vancomycin, as well as combination or sequential dosing with either rifaximin or nitazoxanide. [1] [2] [3] [4] [5] 30, [35] [36] [37] [38] [39] [40] [41] [42] [43] An algorithm outlining our own approach is shown in Figure 2 .
A number of investigational compounds are being developed for use in patients with CDAD, including agents such as tolevamer, ramoplanin and PAR-101. 4, 30 A novel and particularly exciting area of development includes strategies for non-antibiotic-based adjuvant therapy (MoAbs, designer probiotics, vaccines and inhibitors of toxin enzymatic activities). In a related area, the sequence of the C. difficile genome has been determined 44 and will most likely lead to the discovery of yet other molecular regulatory targets for drug development.
Rates and severity of CDAD appear to be increasing in HSCT recipients, a patient population that has an everexpanding extent and variety of risk factors. In the future, particular emphasis should focus on prevention and containment measures along with more formal evaluation of newer agents and combination approaches to the therapy of CDAD in this very challenging population of patients. In the general hospital population, the promotion of antibiotic stewardship programs and the rigorous use of the latest infection control techniques have helped to control a number of CDAD outbreaks and epidemics. 45, 46 For HSCT recipients, larger, more detailed and prospective trials remain warranted for the study of CDAD to more deeply understand the true extent of this problem as well as to determine how this population may differ from other types of patients.
